UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics

Journal of the International AIDS Society, 2022-12, Vol.25 (12), p.e26039-e26039

2022

Link zum Volltext

Verfügbarkeit prüfen

Therapy for Early COVID-19: A Critical Need

JAMA : the journal of the American Medical Association, 2020-12, Vol.324 (21), p.2149

2020

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T Cells, Including Th17 and Cycling Subsets, Are Intact in the Gut Mucosa of HIV-1-Infected Long-Term Nonprogressors

Journal of Virology, 2011-06, Vol.85 (12), p.5880-5888

2011

Link zum Volltext

Verfügbarkeit prüfen

The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants

PloS one, 2010-08, Vol.5 (8), p.e11937

2010

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Translocation of Microbial Products in Patients with Idiopathic CD4 Lymphocytopenia

The Journal of infectious diseases, 2009-06, Vol.199 (11), p.1664-1670

2009

Link zum Volltext

Verfügbarkeit prüfen

Leveraging lessons learned from the COVID-19 pandemic for HIV

Communications medicine, 2022-08, Vol.2 (1), p.110-110, Article 110

2022

Link zum Volltext

Verfügbarkeit prüfen

2019: A Banner Year for Tuberculosis Research

The Journal of infectious diseases, 2020-12, Vol.222 (11), p.1768-1771

2020

Link zum Volltext

Verfügbarkeit prüfen

Opportunistic Infections and Mortality: Still Room for Improvement

The Journal of infectious diseases, 2015-11, Vol.212 (9), p.1348-1350

2015

Link zum Volltext

Verfügbarkeit prüfen

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics

Annals of internal medicine, 2021-09, Vol.174 (9), p.1293

2021

Link zum Volltext

Verfügbarkeit prüfen

HIV Infection and the Gut: Scarred for Life?

The Journal of infectious diseases, 2008-08, Vol.198 (4), p.453-455

2008

Link zum Volltext

Verfügbarkeit prüfen

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials

Critical care medicine, 2021-11, Vol.49 (11), p.1963

2021

Link zum Volltext

Verfügbarkeit prüfen

Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection

The Journal of infectious diseases, 2014-11, Vol.210 (10), p.1549-1554

2014

Link zum Volltext

Verfügbarkeit prüfen

CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients

The Journal of infectious diseases, 2008-09, Vol.198 (6), p.843-850

2008

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation

The Journal of infectious diseases, 2007-09, Vol.196 (5), p.677-683

2007

Link zum Volltext

Verfügbarkeit prüfen

Progress Toward Curing HIV Infections With Hematopoietic Stem Cell Transplantation

Clinical infectious diseases, 2015-01, Vol.60 (2), p.292-297

2015

Link zum Volltext

Verfügbarkeit prüfen

Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance

Blood, 2011-09, Vol.118 (12), p.3244-3253

2011

Link zum Volltext

Verfügbarkeit prüfen

Nanotechnology and HIV: potential applications for treatment and prevention

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2010-11, Vol.2 (6), p.693-702

2010

Link zum Volltext

Verfügbarkeit prüfen

The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients

Journal of acquired immune deficiency syndromes (1999), 2011-04, Vol.56 (4), p.340

2011

Link zum Volltext

Verfügbarkeit prüfen

Delayed sample processing leads to marked decreases in measured plasma IL-7 levels

Journal of acquired immune deficiency syndromes (1999), 2006-08, Vol.42 (4), p.511

2006

Link zum Volltext

Verfügbarkeit prüfen

Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy

Journal of acquired immune deficiency syndromes (1999), 2006-08, Vol.42 (5), p.537

2006

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

AIDS (London), 2011-11, Vol.25 (17), p.2113-2122

2011

Link zum Volltext

Verfügbarkeit prüfen

Rifaximin has a Marginal Impact on Microbial Translocation, T-cell Activation and Inflammation in HIV-Positive Immune Non-responders to Antiretroviral Therapy - ACTG A5286

The Journal of infectious diseases, 2015-03, Vol.211 (5), p.780-790

2015

Link zum Volltext

Verfügbarkeit prüfen

Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels

Mucosal immunology, 2010-03, Vol.3 (2), p.172-181

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(143)
Bücher
(3)
Berichte
(3)
Reviews
(1)

Sprache

Englisch
(149)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics

Therapy for Early COVID-19: A Critical Need

CD4+ T Cells, Including Th17 and Cycling Subsets, Are Intact in the Gut Mucosa of HIV-1-Infected Long-Term Nonprogressors

The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants

Evidence for Translocation of Microbial Products in Patients with Idiopathic CD4 Lymphocytopenia

Leveraging lessons learned from the COVID-19 pandemic for HIV

2019: A Banner Year for Tuberculosis Research

Opportunistic Infections and Mortality: Still Room for Improvement

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics

HIV Infection and the Gut: Scarred for Life?

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials

Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection

CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients

CD4+ T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation

Progress Toward Curing HIV Infections With Hematopoietic Stem Cell Transplantation

Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel

Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance

Nanotechnology and HIV: potential applications for treatment and prevention

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy

The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients

Delayed sample processing leads to marked decreases in measured plasma IL-7 levels

Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Rifaximin has a Marginal Impact on Microbial Translocation, T-cell Activation and Inflammation in HIV-Positive Immune Non-responders to Antiretroviral Therapy - ACTG A5286

Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels

Suchergebnisse filtern